1. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome 
Bart L. Scott, Barry Storer, Michael R. Loken, Rainer Storb, Frederick R. Appelbaum, H.Joachim Deeg 
Biology of Blood and Marrow Transplantation 
Volume 11, Issue 1, Pages (January 2005)
DOI: /j.bbmt
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Overall survival (OS) by flow score severity. A, OS according to the severity of flow score in patients who did not receive IC. B, OS according to the severity of flow score in patients who did receive IC. (Flow indicates flow score; 0–3, low or moderate; 4–9, severe).
Biology of Blood and Marrow Transplantation  , 65-73DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Nonrelapse mortality (NRM). A, NRM according to receipt of IC versus no IC. B, NRM for patients with tAML. C, NRM for patients with RAEB/RAEB-T. The FAB classification was determined before the administration of IC.
Biology of Blood and Marrow Transplantation  , 65-73DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Relapse-free survival (RFS). A, RFS according to receipt of IC versus no IC. B, RFS for patients with tAML. C, RFS for patients with RAEB/RAEB-T. The FAB classification was determined before administration of IC.
Biology of Blood and Marrow Transplantation  , 65-73DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions